With a new month here, I'm sure many readers will be considering a few changes to their portfolio in the near future.
But which shares should you buy? To help narrow things down for you, I have picked out three shares that are highly rated:
Altium Limited (ASX: ALU)
The first ASX share to look at is Altium. It is an award-winning printed circuit board (PCB) design software provider. Over the last few years, Altium has carved out a leading position in this growing market and is now aiming to take things to the next level by dominating it.
A key part of this plan is the recent release its cloud-based Altium 365 product. Management expects this to support its aim of doubling its subscriber numbers to 100,000 and increasing its revenue by ~150% to US$500 million by 2026.
One broker that likes what it sees here is Credit Suisse. Its analysts have an outperform rating and $42.00 price target on the company's shares.
CSL Limited (ASX: CSL)
Another option to consider is CSL. It is one of the world's leading biotechnology companies. It is comprised of the CSL Behring business and the Seqirus business.
CSL Behring is the global number one player in a plasma therapies industry worth a massive US$30 billion per year. Whereas Seqirus is now the number two player in the US$6 billion global influenza vaccines industry.
Analysts at UBS are big fans of the company and note that it has a lucrative research and development pipeline which could support solid growth in the future. The broker has a buy rating and $346.00 price target on its shares.
REA Group Limited (ASX: REA)
A final ASX share to look at is REA Group. It is the leading player in real estate listings in the Australian market.
Although FY 2020 was a difficult year for the company because of the pandemic, its excellent costs control limited the damage. And pleasingly, with the housing market tipped to perform strongly in 2021, it looks well-placed to benefit from a return to listings growth.
In addition to this, price increases, international growth, and flat costs are likely to support its performance.
Morgan Stanley is positive on the company and has an overweight rating and $150.00 price target on its shares.
